Alzheimer’s disease expert Richard S. Isaacson, MD, explores strategies for care collaboration to optimize care for patients with Alzheimer’s disease (AD), the importance of determining patient-specific pharmacologic treatment approaches for patients with AD, and implementing approaches for effective communication with patients and caregivers surrounding AD diagnosis and management.
Dermatology expert Linda Stein Gold, MD, explores the rationale for Janus kinase (JAK) inhibition in atopic dermatitis (AD), clinical trial data on approved and emerging JAK inhibitors in this setting, and the importance of considering JAK inhibitors when creating patient-specific plans for patients with inadequately controlled AD.